This T cell-based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft Corporation (NASDAQ: MSFT). Unlike other tests that detect blood-based antibodies to determine the prior infection with the virus, the T-Detect COVID-19 Test leverages immune repertoire sequencing technology to identify individuals with an adaptive T-cell response to SARS-CoV-2, indicating recent or prior infection. The EUA was issued based on a clinical validation study demonstrating a sensitivity of 97.1% from the date of COVID-19 diagnosis with RT-PCR. The test also showed a specificity of 100%. The FDA noted that the test should not be used to diagnose current SARS-CoV-2 infection.